Alteration of neurosteroids by chronic finasteride use
Prague Med Rep. 2009;110(3):222-30. Related Articles, LinkOut
Finasteride treatment and neuroactive steroid formation.
Duskova M, Hill M, Hanus M, Matouskova M, Starka L.
Institute of Endocrinology, Prague, Czech Republic.
Finasteride is the 5alpha-reductase inhibitor that received clinical
approval for the treatment of human benign prostate hyperplasia and
androgenetic alopecia. The 5alpha-reductase is enzyme responsible for
the reduction of testosterone to dihydrostestosterone, progesterone to
dihydroprogesterone and deoxycorticosterone to
dihydrodeoxycorticosterone, steroids modulating the action of
gamma-aminobutyric acid on GABA receptors. These neuroactive steroids
possess anticonvulsant, antidepressant and anxiolytic effects. The
objective of the study was to determine the effect of finasteride
therapy on a broad steroid spectrum in men with benign prostate
hyperplasia. A group of 20 men with benign prostate hyperplasia was
involved in the present study. Finasteride in the daily dose of 5 mg/
day was administrated for 4 months. In all individuals, their hormonal
profile of steroid hormones was determined before and after 4 months
lasting finasteride treatment. Finasteride treatment resulted in a
significant decrease all alpha-reduced and increase of most
5beta-reduced metabolites of testosterone and progesterone as well as
in an increase of 7alpha-hydoxyderivatives, which are known as
neuroactive steroids acting by modulation of GABAA and NMAD receptors in the
brain.
In the course of finasteride treatment the decrease of the
concentration of circulating steroids with known inhibitory activity on GABA-ergic
excitation in the brain is very probably an important factors
contributing to the development of the symptoms of depression seen in
some isolated cases of finasteride administration.
Publication Types:
* Research Support, Non-U.S. Gov't
PMID: 19655698